Title: Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.
Journal: Oncotarget 20160126
1187214-13-6
1123837-34-2
2244864-88-6
109029-96-1 | 2-Chloro-5-(morpholinosulfonyl)benzoic acid | AA008TVC | MFCD00492872
1173052-99-7 | N-[4-Chloro-3-(morpholin-4-ylsulfonyl)phenyl]-2-(methylamino)acetamide hydrochloride | AA008U3Y | MFCD08448134
1184917-16-5 | 4-Bromo-2,5-dichloropyridine | AA008UDS | MFCD12911586
1204298-58-7 | tert-Butyl 3-amino-1h-indazole-1-carboxylate | AA008UNA | MFCD12827767
118358-38-6 | FMOC-L-SER(BETA-D-GLCAC4)-OH | AA008UY4 | MFCD03452820
1134333-99-5 | 4-(Hydroxymethyl)-5-methylisoxazole-3-carboxylic acid | AA008V40 | MFCD12030889
1208075-25-5 | 2-Chloro-6-fluorobenzene-1-sulfonyl chloride | AA008VAU | MFCD12026157
10486-51-8 | 4-Chlorosulfonyl-benzoic acid ethyl ester | AA008VFY | MFCD00121815
1033078-12-4 | (R,S)-N2-Nitroso-Anabasine N'-β-D-Glucuronide | AA008VKZ | MFCD28898584
1175129-26-6 | delta-5(6)-Didehydronorethindrone acetate | AA008VTX | MFCD11114037
